Evidence map›Paper›PMID 39359099›Full record

ReviewThe FEBS journal2025

Glycaemic sugar metabolism and the gut microbiota: past, present and future.

Florine H M Westerbeke, Ilias Attaye, Melany Rios-Morales, Max Nieuwdorp

Abstract readReview
In one paragraph

Review in The FEBS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. AnmSystems · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Florine H M WesterbekeDepartment of Internal and Experimental Vascular Medicine, Amsterdam University Medical Centers, location AMC, The Netherlands.ORCID 0009-0007-1860-7520
Ilias AttayeDepartment of Internal and Experimental Vascular Medicine, Amsterdam University Medical Centers, location AMC, The Netherlands.
Melany Rios-MoralesDepartment of Internal and Experimental Vascular Medicine, Amsterdam University Medical Centers, location AMC, The Netherlands.
Max NieuwdorpDepartment of Internal and Experimental Vascular Medicine, Amsterdam University Medical Centers, location AMC, The Netherlands.ORCID 0000-0002-1926-7659

Funding

Amsterdam Cardiovascular Sciences, Amsterdam University Medical CentersZonMw 09150182010020
6 · The paper itself

Abstract

Non-communicable diseases (NCDs), such as type 2 diabetes (T2D) and metabolic dysfunction-associated fatty liver disease, have reached epidemic proportions worldwide. The global increase in dietary sugar consumption, which is largely attributed to the production and widespread use of cheap alternatives such as high-fructose corn syrup, is a major driving factor of NCDs. Therefore, a comprehensive understanding of sugar metabolism and its impact on host health is imperative to rise to the challenge of reducing NCDs. Notably, fructose appears to exert more pronounced deleterious effects than glucose, as hepatic fructose metabolism induces de novo lipogenesis and insulin resistance through distinct mechanisms. Furthermore, recent studies have demonstrated an intricate relationship between sugar metabolism and the small intestinal microbiota (SIM). In contrast to the beneficial role of colonic microbiota in complex carbohydrate metabolism, sugar metabolism by the SIM appears to be less beneficial to the host as it can generate toxic metabolites. These fermentation products can serve as a substrate for fatty acid synthesis, imposing negative health effects on the host. Nevertheless, due to the challenging accessibility of the small intestine, our knowledge of the SIM and its involvement in sugar metabolism remains limited. This review presents an overview of the current knowledge in this field along with implications for future research, ultimately offering potential therapeutic avenues for addressing NCDs.

Indexed as

Carbohydrate MetabolismDiabetes Mellitus, Type 2Gastrointestinal MicrobiomeAnimalsFructoseGlucoseHumansInsulin ResistanceIntestine, SmallFructoseGlucosegut microbiotanon‐communicable diseasessmall intestinal microbiotasmall intestinesugar metabolism

Identifiers

PMID39359099
PMCPMC11927047

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.